260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO, CA
Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
News, Securities Holder Rights or Indentures
Minnie Kuo Appointed Chief Operating Officer at Pliant Therapeutics
Departure of Chief Medical Officer Éric Lefebvre Effective December 15, 2025
Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Departure of Chief Business Officer - Hans Hull Resigns from Pliant Therapeutics
Pliant Therapeutics Completes $32.4 Million Loan Prepayment
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Registration of Securities
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRER14A
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership